Pharmaceuticals

A novel universal antiviral drug introduced in Korea

- Hyundai Bioscience launches CP-COV03 Phase 2 clinical trials - "To be an innovative medicine like penicillin that led to victory in the bacterial war" - Significant changes to the 'vaccine-dependent' virus response system SEOUL, South Korea, May 12, 2022 /PRNewswire/ -- The birth of a universa...

2022-05-12 18:19 3981

Zhimeng Biopharma Announces Dosing of First Subject of Its Novel Antiepileptic Drug Candidate CB03 in First-in-Human Phase I Clinical Trial

SHANGHAI, May 11, 2022 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng"), announced dosing of the first participant in the US Phase I study in healthy subjects of its innovative small-molecule KCNQ2/3 selective opener (CB03), developed for the treatment of refractory epilepsy. CB03 is...

2022-05-12 08:00 2069

Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead™ Programs at the TIDES USA 2022

GAITHERSBURG, Md. and SUZHOU, China, May 11, 2022 /PRNewswire/ -- Sirnaomics Ltd.  ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments o...

2022-05-11 13:05 3648

Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab) for Immune Restoration/Functional Cure of HIV-1 Infected Patients

HANGZHOU, China and SHAOXING, China, May 11, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today the Investigational New Drug (IND) application approval of ASC22 (Envafolimab) by U.S. Food and Drug Administration (FDA) for the indication of immune restoration/functi...

2022-05-11 08:40 4192

RhoVac AB announces Database Lock in its clinical phase IIb trial of onilcamotide

STOCKHOLM, Sweden, May 11, 2022  /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company,announced on May 10th, 2022, that its phase IIb study in prostate cancer, BRaVac, has reached "Database Lock". This means that all data from the trial is now finally reported, cleaned and...

2022-05-11 06:42 2491

Bridge Biotherapeutics to Announce Updated Data from its Phase 1 Study of BBT-176 in Advanced Non-Small Cell Lung Cancer in an Oral Presentation at IASLC 2022 World Conference on Lung Cancer

* Data analysis to explore demonstrated anti-tumor activity of BBT-176, a fourth generation EGFR TKI, in advanced non-small cell lung cancer SEONGNAM, South Korea , May 10 /PRNewswire/ -- Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on deve...

2022-05-10 21:00 2521

Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen's CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers

SHANGHAI, May 10, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the phase I trial interim results of an investigator-initiated tri...

2022-05-10 20:50 2729

Bora Pharmaceuticals acquires Eden Biologics CDMO Assets

Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market TAIPEI, May 10, 2022 /PRNewswire/ -- Taiwan-based premier international contract development and manufacturing organization (CDMO) Bora Pharmaceuticals recently announced the esta...

2022-05-10 17:53 5010

Harbour BioMed to Present the Latest Progress of Next-Generation Anti-CTLA-4 Antibody HBM4003 at 2022 ASCO Annual Meeting

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 10, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, today announced the Company w...

2022-05-10 16:54 3348

OMRON Healthcare Unveils Long-term Corporate Vision, "Going for ZERO, Preventive Care for Health of Society"

- Aiming to Realize 3 Zeros: "Zero Cerebrovascular and Cardiovascular Events," "Zero Aggravation of Respiratory Diseases" and "Zero Restrictions on Daily Activities Due to Chronic Pain" - KYOTO, Japan, May 10, 2022 /PRNewswire/ -- In March 2022, OMRON Group announced a new long-term vision, "Sha...

2022-05-10 13:00 3928

Robert Wessman-led Aztiq completes $500 million transaction in an alliance with Innobic to create an international pharma powerhouse

* The Consortium jointly, through Aztiq II HoldCo, has completed the acquisition of a 100% stake in Alvogen Emerging Markets Holdings Limited, thereby becoming the leading shareholders in Lotus Pharmaceuticals and Adalvo * Róbert Wessman, Chairman and CEO of Alvogen and Founder of Aztiq Pharma ...

2022-05-10 11:00 3122

AffaMed Therapeutics Holds DEXTENZA Launch and Advisory Board Meeting in Macau

SHANGHAI, May 9, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, held a DEXTENZA Launch and Advisory Board Meeting recently inMacau, f...

2022-05-10 09:00 2118

iNtRON Biotechnology, Inc., Launches New Website

It aims to promote strategic collaborations in global while also highlights its many innovative advances and successful scientific ventures. BOSTON and SEOUL, South Korea, May 9, 2022 /PRNewswire/ -- The parent company of iNtODEWORLD, Inc., iNtRON Biotechnology, Inc., ("iNtRON" or "Company") is ...

2022-05-09 21:00 2995

Brii Bio Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant

* Studies conducted by independent labs demonstrate the amubarvimab/romlusevimab combination retains neutralizing activity against COVID-19 Omicron variant * Review of the monoclonal antibody combination therapy is underway by the U.S. Food and Drug Administration (FDA) for Emergency Use Auth...

2022-05-09 19:46 3711

Series A financing round lays foundation for international growth of digital cancer therapeutics Mika

New investors with a successful track record in digital oncology support German Digital Therapeutics (DTx) company Fosanis to broaden patient access of Mika – an app-based DTx platform empowering people affected by cancer. BERLIN, LAUSANNE,Switzerland, BARCELONA,Spain and MUNICH, May 9, 2022 /PR...

2022-05-09 19:35 2694

Takeda Malaysia receives coveted HR accolades by creating an exceptional people experience

Key points: * Takeda Malaysia receives Great Place to Work® award for the first time and Top Employer certification for the sixth consecutive year. * A significant majority of employees surveyed in Malaysia in 2021 Great Place to Work® Trust Index stated that Takeda is a great workplace. * ...

2022-05-09 09:05 2979

Takeda Singapore receives coveted HR accolades by creating an exceptional people experience

Key points: * Takeda Singapore receives Great Place to Work® award for the first time and Top Employer certification for the sixth consecutive year. * A significant majority of employees surveyed in Singapore in 2021 Great Place to Work® Trust Index stated that Takeda is a great workplace. ...

2022-05-09 09:00 2916

InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers

NANJING, China, May 8, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors, today announced that it had completed $15 million in Series B+ Fin...

2022-05-09 08:04 2384

ExoCoBio Receives Japanese Patent for Alleviating Dermatitis with Adipose Stem Cell-Derived Exosome

* To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment * To prove the technological feasibility of ExoSCRT™ for the mass-production of the world's best exosomes with high efficacy SEOUL, Korea, May 9, 2022 /PRNewswire/ -- ExoC...

2022-05-09 07:00 5236

Brii Bio Reports Progress on ESG Commitments in Its Inaugural ESG Report

DURHAM, N.C. and BEIJING, May 7, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company," stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health...

2022-05-07 09:00 6654
1 ... 285286287288289290291 ... 345